487.61

0.54% -2.63

After Hours: 487.61

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $487.61, with a volume of 326.99K. It is down -0.54% in the last 24 hours and down -5.99% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Previous Close:

$490.24

Open:

$484.33

24h Volume:

326.99K

Relative Volume:

0.68

Market Cap:

$20.91B

Revenue:

$3.17B

Net Income/Loss:

$1.29B

P/E Ratio:

18.00

EPS:

27.0947

Net Cash Flow:

$1.01B

1W Performance:

-5.40%

1M Performance:

-5.99%

6M Performance:

-0.53%

1Y Performance:

+28.16%

1-Day Range:

$484.33

$494.08

1-Week Range:

$477.01

$517.75

52-Week Range:

$375.61

$609.35

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,400

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

UTHR's Discussions on Twitter

Compare UTHR vs TAK, TEVA, HLN, ZTS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Outperform
Oct-20-25	Initiated	Wells Fargo	Underweight
Sep-26-25	Initiated	RBC Capital Mkts	Outperform
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

Aug 21, 2026

United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan

Aug 21, 2026

United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan

Aug 21, 2026

Aug 20, 2026

United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan

Aug 20, 2026

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill

Aug 20, 2026

Aug 19, 2026

ETFs Investing in United Therapeutics Corporation Stocks - TradingView

Aug 19, 2026

United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan

Aug 19, 2026